Recent developments and therapeutic strategies against hepatocellular carcinoma

Mark Yarchoan, Parul Agarwal, Augusto Villanueva, Shuyun Rao, Laura A. Dawson, Josep M. Llovet, Richard S. Finn, John D. Groopman, Hashem B. El-Serag, Satdarshan P. Monga, Xin Wei Wang, Michael Karin, Robert E. Schwartz, Kenneth K. Tanabe, Lewis R. Roberts, Preethi H. Gunaratne, Allan Tsung, Kimberly A. Brown, Theodore S. Lawrence, Riad SalemAmit G. Singal, Amy K. Kim, Atoosa Rabiee, Linda Resar, Yujin Hoshida, Aiwu Ruth He, Kalpana Ghoshal, Patrick B. Ryan, Elizabeth M. Jaffee, Chandan Guha, Lopa Mishra, C. Norman Coleman, Mansoor M. Ahmed

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.

Original languageEnglish (US)
Pages (from-to)4326-4330
Number of pages5
JournalCancer Research
Issue number17
StatePublished - Sep 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Recent developments and therapeutic strategies against hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this